State of Alaska Department of Revenue Acquires 1,170 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

State of Alaska Department of Revenue increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 2.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,789 shares of the medical equipment provider's stock after buying an additional 1,170 shares during the quarter. State of Alaska Department of Revenue's holdings in Intuitive Surgical were worth $20,696,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ISRG. Onefund LLC grew its position in Intuitive Surgical by 1.9% during the fourth quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock valued at $494,000 after acquiring an additional 18 shares during the last quarter. AlphaCore Capital LLC lifted its holdings in shares of Intuitive Surgical by 4.2% in the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after acquiring an additional 18 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Intuitive Surgical by 2.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock valued at $390,000 after purchasing an additional 19 shares in the last quarter. Accredited Investors Inc. boosted its stake in shares of Intuitive Surgical by 1.9% in the 4th quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after purchasing an additional 19 shares in the last quarter. Finally, Second Line Capital LLC grew its holdings in shares of Intuitive Surgical by 3.4% during the 4th quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after purchasing an additional 19 shares during the last quarter. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Trading Down 0.5%

NASDAQ ISRG traded down $2.62 during trading on Thursday, hitting $509.49. The company had a trading volume of 1,173,748 shares, compared to its average volume of 1,675,866. The company's fifty day moving average is $527.71 and its 200-day moving average is $537.69. Intuitive Surgical, Inc. has a one year low of $413.82 and a one year high of $616.00. The company has a market cap of $182.61 billion, a price-to-earnings ratio of 74.71, a price-to-earnings-growth ratio of 5.40 and a beta of 1.67.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. The company had revenue of $2.25 billion for the quarter, compared to analysts' expectations of $2.19 billion. During the same quarter in the previous year, the company earned $1.50 earnings per share. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on ISRG shares. Royal Bank Of Canada lowered their price target on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Robert W. Baird decreased their price objective on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Piper Sandler lowered their target price on Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating for the company in a research note on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and reduced their price target for the stock from $515.00 to $440.00 in a research report on Monday, June 9th. Finally, BTIG Research set a $560.00 price target on Intuitive Surgical and gave the stock a "buy" rating in a research note on Monday, April 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $588.95.

Insiders Place Their Bets

In other news, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the transaction, the senior vice president now owns 907 shares in the company, valued at $510,740.77. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jami K. Nachtsheim sold 2,400 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the sale, the director now directly owns 6,371 shares in the company, valued at approximately $3,312,920. The trade was a 27.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,998 shares of company stock worth $2,611,577. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.